Prostacyclin receptor agonists

Mechanism of action and pharmacologic effects

Drugs of this group, the main representative of which is epoprostenol, work by directly stimulating specific prostacyclin receptors. Essentially, they reproduce the effects of natural prostacyclin, which normally functions as a natural antiplatelet agent.

The most important pharmacodynamic feature of these drugs is that they act as functional antagonists of thromboxane $A_2$. This means that the drugs produce effects directly opposite to those of thromboxane while acting on their own receptors.

Key pharmacological effects:

• Antiplatelet effect: the drugs effectively reduce the ability of platelets to aggregate, preventing them from clumping together.
• Vascular effect: pronounced vasodilation (widening of blood vessels) is observed, which naturally leads to a systemic decrease in blood pressure (BP).

Pharmacokinetic features

The pharmacokinetics of prostacyclin preparations is extremely peculiar and imposes strict limitations on the routes of their administration into the patient's body. The main clinical problem lies in the extremely short duration of the active substance's presence in the systemic circulation.

The half-life ($t_{1/2}$) of epoprostenol is only about two minutes. Upon entering the bloodstream, the drug molecule undergoes very rapid degradation. Due to such rapid inactivation, traditional routes of administration (such as oral intake, intramuscular injections, or sublingual use) are completely ineffective.

To maintain a therapeutic concentration and ensure a stable pharmacological effect, the drug requires continuous infusion administration. Only continuous intravenous delivery makes it possible to compensate for the rapid destruction of the substance in blood plasma and maintain the required level of vasodilation and antiplatelet activity.

Clinical application

The specific profile of action and complex pharmacokinetics determine a rather narrow niche for the use of these drugs in modern medical practice.

1. Treatment of pulmonary hypertension. This is the main area of use for drugs in this group. Therapeutic success here is achieved due to the pronounced vasodilating effect, which effectively reduces blood pressure in the vessels.
2. Prevention of thrombosis (limited use). Despite their pronounced antiplatelet potential, these drugs are not widely used as standard agents for the prevention of thrombosis. The main limiting factor is precisely their short duration of action. Nevertheless, a potential clinical niche exists: the prevention of platelet aggregation during extracorporeal circulation, where constant control over blood clotting in the apparatus circuit is required.

Class and exam questions

What else to study on this topic

• Mechanisms of vasodilation upon stimulation of prostacyclin receptors.
• Interaction of prostacyclin and thromboxane A2 in the hemostasis system.
• Dosing characteristics during continuous infusion of epoprostenol.
• The role of the vasodilating effect in the treatment of pulmonary hypertension.
• The problem of platelet aggregation during extracorporeal circulation.

Other topics in the section "Drugs affecting hemostasis and thrombosis"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.